Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study.
Nancy U LinMark D PegramSolmaz SahebjamNuhad K IbrahimAnita FungAnna ChengAlan NicholasWhitney P KirschbrownPriya KumthekarPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Although the CNS ORR was modest, 68% of patients experienced clinical benefit, and two patients had ongoing stable intracranial and extracranial disease for > 2 years. High-dose trastuzumab for HER2-positive CNS metastases may warrant further study.
Keyphrases
- high dose
- metastatic breast cancer
- end stage renal disease
- ejection fraction
- newly diagnosed
- phase ii study
- low dose
- epidermal growth factor receptor
- small cell lung cancer
- blood brain barrier
- multiple sclerosis
- peritoneal dialysis
- brain metastases
- clinical trial
- randomized controlled trial
- stem cell transplantation
- squamous cell carcinoma
- radiation therapy
- patient reported outcomes
- tyrosine kinase
- locally advanced
- optical coherence tomography